Open AccessEye-Sparing Treatment for Diffuse Invasive Conjunctival Melanoma
Author(s) -
Leandro Chaves,
Bradley J. Huth,
James J. Augsburger,
Zélia M. Corrêa
Publication year - 2018
Publication title -
ocular oncology and pathology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.444
H-Index - 10
eISSN - 2296-4681
pISSN - 2296-4657
DOI - 10.1159/000485978
Subject(s) - medicine , debulking , melanoma , tumor debulking , histopathology , biopsy , ipilimumab , sentinel lymph node , distant metastasis , radiation therapy , brachytherapy , metastasis , radiology , mucosal melanoma , lymph node , surgery , pathology , chemotherapy , cancer , immunotherapy , ovarian cancer , cancer research , breast cancer
The management of patients with diffuse invasive conjunctival melanoma focuses on local tumor control and screening for metastasis. Despite the lack of consensus on the benefit of sentinel lymph node biopsy for these neoplasms, the information obtained by histopathology is useful for tumor staging and treatment planning. Due to the lack of evidence of survival improvement, orbital exenteration is being performed with diminishing frequency. We describe a patient with diffuse invasive conjunctival melanoma and lymph node involvement treated by tumor debulking, brachytherapy (custom unshielded radioactive device), and adjuvant ipilimumab who has had a favorable outcome without emergence of local tumor relapse or distant metastasis during 16 months of follow up.